~(125)I放射性粒子术中植入联合吉西他滨治疗局部进展期胰腺癌的临床研究

目的探讨放射性125I粒子植入联合吉西他滨治疗进展期胰腺癌的临床价值。方法2001年8月～2006年9月,64例局部进展期胰腺癌患者随机分成两组:A组32例(125I粒子 吉西他滨),B组32例(吉西他滨),分析放射性125I粒子永久植入联合吉西他滨治疗局部进展期胰腺癌的疗效,毒副反应及生存率。结果A,B两组CR PR MR SD分别为81.25%(26/32),71.88%(23/32),两组比较差异有显著性(P<0.05)。两组毒性反应率和并发症发生率基本没有差异(P>0.05)。术后6个月和12个月生存率A组为75.0%,37.5%,明显高于B组的40.0%,12.5%(P<0.05)。结论放射性125I粒子植入联合吉西他滨化疗对进展期胰腺癌能提高患者生存率,是一种安全有效的治疗手段。

125I radioactive particles implanted into tumor combind with gemcitabine to treat extended local pancreas cancer

[Objective] To explore the significance of implanted 125I radioactive particles into tumor combined with gemcitabine to treat extended local pancreas cancer. [Method] 64 patients treated for locally advanced pancreatic cancer were collected and randomized into two group: group A-125I gemcitabine 32 patints and B-gemcitabine 32 patints. Cure results, complication and survival rate of 64 cases extended local pancreas were analyzed prespectively. [Result] CR PR MR SD of group A was 81.25% (26/32), and the difference between two groups was statistical significance (P <0.05). The rate of complicatiom of group A was higher than that of group B without statistical significance (P >0.05). Survival rate of 6 and 12 months in group A (75%, 37.5%) was higher than that in group B (40%, 12.5%) (P <0.05). [Conclusion] Implanted 125I radioactive particles into tumor combined with gemcitabine to treat extended local pancreas cancer can improve survival rate. It is a safe and effective method.